» Articles » PMID: 1974025

Effects of Ketone Bodies on Carbohydrate Metabolism in Non-insulin-dependent (type II) Diabetes Mellitus

Overview
Journal Metabolism
Specialty Endocrinology
Date 1990 Aug 1
PMID 1974025
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of ketone bodies to suppress elevated hepatic glucose output was investigated in eight postabsorptive subjects with non-insulin-dependent diabetes mellitus (NIDDM). Infusion of sodium acetoacetate alone (20 mumols/kg/min) for 3 hours increased total serum ketones (beta-hydroxybutyrate and acetoacetate) to approximately 6 mmol/L, but did not reduce plasma glucose (14.0 +/- 0.8 to 12.3 +/- 0.9 mmol/L) or isotopically determined hepatic glucose output (17.5 +/- 1.4 to 12.7 +/- 1.0 mumols/kg/min) more than saline alone. Plasma C-peptide concentrations were unchanged, while serum glucagon increased from 131 +/- 13 to 169 +/- 24 ng/mL (P less than .015) and free fatty acids were suppressed by 43% (0.35 +/- 0.08 to 0.20 +/- 0.06 mmol/L, P less than .025). When sodium acetoacetate was infused with somatostatin (0.10 micrograms/kg/min) to suppress glucagon and insulin secretion, the decrease in both plasma glucose (13.3 +/- 0.9 to 10.2 +/- 0.7 mmol/L) and hepatic glucose output (17.2 +/- 1.6 to 9.4 +/- 0.6 mumols/kg/min) was greater than either acetoacetate or somatostatin infusion alone. Infusion of equimolar amounts of sodium bicarbonate had no effect on glucose metabolism. In conclusion, these results demonstrate that ketone bodies can directly suppress elevated hepatic glucose output in NIDDM independent of changes in insulin secretion, but only when the concomitant stimulation of glucagon secretion is prevented. Ketone bodies also suppress adipose tissue lipolysis in the absence of changes in plasma insulin and may serve to regulate their own production.

Citing Articles

Therapeutic potential of β-hydroxybutyrate in the management of pancreatic neoplasms: exploring novel diagnostic and treatment strategies.

Vaezi M, Nekoufar S, Robati A, Salimi V, Tavakoli-Yaraki M Lipids Health Dis. 2024; 23(1):376.

PMID: 39543582 PMC: 11562866. DOI: 10.1186/s12944-024-02368-7.


Exogenous ketone supplementation: an emerging tool for physiologists with potential as a metabolic therapy.

Falkenhain K, Islam H, Little J Exp Physiol. 2022; 108(2):177-187.

PMID: 36533967 PMC: 10103874. DOI: 10.1113/EP090430.


Could Dietary Modification Independent of Energy Balance Influence the Underlying Pathophysiology of Type 2 Diabetes? Implications for Type 2 Diabetes Remission.

Guess N Diabetes Ther. 2022; 13(4):603-617.

PMID: 35266093 PMC: 8991239. DOI: 10.1007/s13300-022-01220-4.


Comparing the Efficacy and Safety of Low-Carbohydrate Diets with Low-Fat Diets for Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Li S, Ding L, Xiao X Int J Endocrinol. 2021; 2021:8521756.

PMID: 34912453 PMC: 8668312. DOI: 10.1155/2021/8521756.


Exogenous d-β-hydroxybutyrate lowers blood glucose in part by decreasing the availability of L-alanine for gluconeogenesis.

Soto-Mota A, Norwitz N, Evans R, Clarke K Endocrinol Diabetes Metab. 2021; 5(1):e00300.

PMID: 34787952 PMC: 8754249. DOI: 10.1002/edm2.300.